DCT

2:26-cv-03803

Bausch Health Ireland Ltd v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-03803, D.N.J., 04/10/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Zydus USA maintains its principal place of business in the state. Venue over Zydus Lifesciences, a foreign corporation, is alleged to be proper in any district where it is subject to personal jurisdiction.
  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) for a generic version of the topical acne treatment CABTREO® constitutes an act of infringement of four U.S. patents related to topical pharmaceutical compositions.
  • Technical Context: The technology concerns fixed-dose, triple-combination topical gel formulations for the treatment of acne, a highly prevalent dermatological condition.
  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Plaintiff's receipt of a Paragraph IV certification notice letter from Defendant. In the letter, Defendant asserts that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product. The asserted patents are listed in the U.S. Food and Drug Administration's "Orange Book" in connection with Plaintiff's CABTREO® product.

Case Timeline

Date Event
2019-08-01 Priority Date for all Asserted Patents
2022-07-19 U.S. Patent No. 11,389,467 Issued
2023-10-20 FDA Approved New Drug Application for CABTREO®
2024-10-29 U.S. Patent No. 12,128,059 Issued
2024-11-05 U.S. Patent No. 12,133,859 Issued
2024-11-12 U.S. Patent No. 12,138,278 Issued
2026-02-26 Plaintiff Received Defendant's Paragraph IV Notice Letter
2026-04-10 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,389,467 - "Topical Compositions"

The Invention Explained

  • Problem Addressed: The patent's background section describes the technical challenges of creating effective combination therapies for acne Compl. ¶31 '467 Patent, col. 2:16-20 Combining multiple active ingredients can lead to unpredictable chemical interactions, such as the oxidation of other components by benzoyl peroxide, potentially reducing the formulation's stability and efficacy Compl. ¶31 '467 Patent, col. 2:44-56 Previous attempts to create triple-combination therapies were not shown to be clinically superior to dual-therapies Compl. ¶31 '467 Patent, col. 2:28-35
  • The Patented Solution: The invention is a specific topical gel formulation that combines three active pharmaceutical ingredients-clindamycin phosphate, benzoyl peroxide, and adapalene-in a stable and effective manner Compl. ¶31 '467 Patent, abstract The solution relies on a particular combination of a gelling agent, a polyhydric alcohol, and water, formulated within a specific pH range, to create a fixed-dose product that can be applied once daily Compl. ¶31 '467 Patent, col. 3:11-17 This approach is intended to enhance patient adherence and provide superior efficacy compared to treatments involving fewer active agents Compl. ¶31 '467 Patent, col. 3:3-10
  • Technical Importance: The invention provides a single-product, triple-combination therapy for acne, simplifying treatment regimens and potentially offering enhanced efficacy by targeting multiple pathogenic features of the condition simultaneously Compl. ¶31 '467 Patent, col. 2:1-2

Key Claims at a Glance

  • The complaint asserts infringement of at least one claim, and notes Defendant did not contest infringement of claims 1-8 and 10-21 in its notice letter Compl. ¶47 Independent claim 1 is representative.
  • Claim 1 Elements:
    • A topical gel formulation comprising
    • active ingredients of 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene,
    • in combination with a gelling agent,
    • an additional agent as a polyhydric alcohol, and
    • water,
    • wherein said benzoyl peroxide is not encapsulated or entrained in a microsponge.
  • The complaint reserves the right to assert other claims Compl. ¶49

U.S. Patent No. 12,128,059 - "Topical Compositions"

The Invention Explained

  • Problem Addressed: As a continuation of the application leading to the '467 Patent, the '059 Patent addresses the same technical problem: the difficulty of creating a stable and effective fixed-dose topical gel containing three different active ingredients for treating acne Compl. ¶32 '059 Patent, col. 2:19-24 The background highlights that prior combination products were often unpredictable and that triple-combination treatments had not demonstrated a clinical advantage over dual therapies Compl. ¶32 '059 Patent, col. 2:24-35
  • The Patented Solution: The '059 Patent discloses a topical gel formulation that successfully combines clindamycin phosphate, benzoyl peroxide, and adapalene Compl. ¶32 '059 Patent, abstract The invention achieves stability and efficacy through a specific composition that includes a gelling agent, a polyhydric alcohol, and water, all maintained at a controlled pH, allowing for a simplified, once-daily application Compl. ¶32 '059 Patent, col. 3:15-21
  • Technical Importance: This solution offers the clinical convenience and potentially superior efficacy of a triple-action acne therapy in a single formulation, overcoming known stability and delivery challenges associated with combining these specific active ingredients Compl. ¶32 '059 Patent, col. 3:3-14

Key Claims at a Glance

  • The complaint asserts infringement of at least one claim, and notes Defendant did not contest infringement of claims 1-8 and 10-19 in its notice letter Compl. ¶59 Independent claim 1 is representative.
  • Claim 1 Elements:
    • A topical gel formulation comprising:
    • 1-1.5 wt. % clindamycin phosphate;
    • 2.5-3.5 wt. % benzoyl peroxide;
    • about 0.15-0.2 wt. % adapalene;
    • a gelling agent;
    • a polyhydric alcohol; and
    • water,
    • wherein the gelling agent is selected from a specified group of polymers.
  • The complaint reserves the right to assert other claims Compl. ¶61

U.S. Patent No. 12,133,859 - "Topical Compositions"

  • Technology Synopsis: The '859 Patent, part of the same patent family, is directed to a topical gel formulation for treating inflammatory skin conditions like acne Compl. ¶33 '859 Patent, abstract The invention provides a stable, fixed-dose combination of clindamycin phosphate, benzoyl peroxide, and adapalene, overcoming the chemical incompatibility and formulation challenges inherent in combining these three active agents Compl. ¶33 '859 Patent, col. 2:19-24
  • Asserted Claims: At least one claim, with the complaint noting that Defendant's notice letter did not contest infringement of claims 1-20 Compl. ¶71
  • Accused Features: The Zydus ANDA Product, which is alleged to be a generic copy of Plaintiff's triple-combination CABTREO® gel, is accused of infringement Compl. ¶¶39-41

U.S. Patent No. 12,138,278 - "Topical Compositions"

  • Technology Synopsis: Also in the same patent family, the '278 Patent claims a topical gel formulation that successfully combines the three active ingredients of clindamycin phosphate, benzoyl peroxide, and adapalene Compl. ¶34 '278 Patent, abstract The formulation uses specific excipients, including a gelling agent and a polyhydric alcohol, to create a stable and effective once-daily treatment for acne Compl. ¶34 '278 Patent, col. 3:15-21
  • Asserted Claims: At least one claim, with the complaint noting that Defendant's notice letter did not contest infringement of claims 1-20 Compl. ¶83
  • Accused Features: The complaint alleges that the formulation of the Zydus ANDA Product infringes the '278 Patent Compl. ¶¶39-41

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is the "Zydus ANDA Product," a generic topical gel containing clindamycin phosphate (1.2%), adapalene (0.15%), and benzoyl peroxide (3.1%) Compl. ¶2 Defendant Zydus is seeking FDA approval to market this product under ANDA No. 220161 Compl. ¶2

Functionality and Market Context

  • The Zydus ANDA Product is a pharmaceutical formulation intended for the topical treatment of acne Compl. ¶36 The complaint alleges that the product is "the same, or substantially the same, as CABTREO®" and contains the "same active ingredients in the same dosages" Compl. ¶41 Compl. ¶44
  • The product is positioned as a generic equivalent to Plaintiff's branded CABTREO® drug Compl. ¶39 The filing of the ANDA is a statutory act of infringement intended to clear a path for Zydus to enter the market and compete with Bausch Health upon receiving FDA approval Compl. ¶48

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis or a claim chart. The central allegation is that Zydus's submission of its ANDA, which seeks approval for a product that is bioequivalent to CABTREO®, constitutes infringement under 35 U.S.C. § 271(e)(2) Compl. ¶48 The infringement theory is based on the allegation that the Zydus ANDA Product necessarily contains a formulation that meets every limitation of the asserted claims Compl. ¶43

11,389,467 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical gel formulation comprising active ingredients of 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene... The Zydus ANDA Product is a topical gel formulation containing 1.2% clindamycin phosphate, 3.1% benzoyl peroxide, and 0.15% adapalene. ¶2 col. 3:12-15
...in combination with a gelling agent... The Zydus ANDA Product is a generic equivalent of CABTREO® and is alleged to contain the necessary excipients, including a gelling agent, to form a stable gel. ¶41 col. 3:15-17
...an additional agent as a polyhydric alcohol, and water... The Zydus ANDA Product is a generic equivalent of CABTREO® and is alleged to contain the necessary excipients, including a polyhydric alcohol and water. ¶41 col. 3:15-17
...wherein said benzoyl peroxide is not encapsulated or entrained in a microsponge. The Zydus ANDA Product is alleged to be the same or substantially the same as CABTREO®, which corresponds to a formulation where the benzoyl peroxide is not encapsulated. ¶41 col. 3:65-col. 4:1

12,128,059 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical gel formulation comprising: 1-1.5 wt. % clindamycin phosphate; 2.5-3.5 wt. % benzoyl peroxide; about 0.15-0.2 wt. % adapalene... The Zydus ANDA Product is a topical gel containing 1.2% clindamycin phosphate, 3.1% benzoyl peroxide, and 0.15% adapalene. ¶2 col. 3:18-21
...a gelling agent; a polyhydric alcohol; and water... The Zydus ANDA Product, being a generic version of the CABTREO® gel, is alleged to contain a gelling agent, a polyhydric alcohol, and water. ¶41 col. 3:18-21
...wherein the gelling agent is selected from the group consisting of [specified polymers] The complaint does not specify the gelling agent in the Zydus product but alleges the product is the same or substantially the same as CABTREO®, implying it uses a claimed gelling agent. ¶41 col. 4:1-12

Identified Points of Contention

  • Scope Questions: Because the Zydus ANDA Product is intended to be a copy of CABTREO®, the central dispute is less likely to be about literal infringement and more about claim validity or claim construction. A key question may be whether Zydus can design around the claims by using an excipient (e.g., a gelling agent or polyhydric alcohol) that it argues falls outside the patent's definition of those terms, thereby creating a non-infringement argument despite bioequivalence.
  • Technical Questions: A potential point of contention could arise from the negative limitation in claim 1 of the '467 Patent requiring that benzoyl peroxide is "not encapsulated or entrained in a microsponge." The question may be whether Zydus's formulation uses any stabilization technique for the reactive benzoyl peroxide that could be characterized as a form of encapsulation or entrainment, even if it is not a traditional "microsponge."

V. Key Claim Terms for Construction

  • The Term: "gelling agent" (appears in claim 1 of all asserted patents)

  • Context and Importance: The identity and concentration of the gelling agent are critical to the formulation's physical properties, stability, and drug release characteristics. A defendant in an ANDA case may argue that its chosen gelling agent, while creating a bioequivalent product, is technically distinct from the agents described and claimed in the patent. The definition of this term will therefore be central to the infringement analysis.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specifications provide a long, non-exhaustive list of potential gelling agents, including various celluloses, carboxyvinyl polymers (carbomers), acrylates, and gums, suggesting the inventors envisioned a broad class of suitable compounds '467 Patent, col. 4:1-12
    • Evidence for a Narrower Interpretation: The specifications identify a "carbomer homopolymer Type C" as the gelling agent used in the specific, preferred embodiment that was clinically tested '467 Patent, col. 4:26-31 '467 Patent, col. 11, Table 1 A defendant may argue that the claims should be construed more narrowly to cover only this specific class of carbomer or those with similar properties, rather than the entire universe of listed examples.

  • The Term: "not encapsulated or entrained in a microsponge" (appears in claim 1 of the '467 Patent)

  • Context and Importance: This negative limitation is used to distinguish the invention from prior art that may have used encapsulation to stabilize reactive ingredients. The interpretation of what constitutes "encapsulation" or "entrainment" is critical. If Zydus's formulation uses a novel polymer or complexing agent to stabilize benzoyl peroxide, the dispute will focus on whether that method falls within the scope of the prohibited structures.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification contrasts the invention with such prior art, and a related limitation states the benzoyl peroxide is "free and unrestricted by any complex or polymer" '467 Patent, col. 3:65-col. 4:1 This language may support a broad exclusion of any technology that physically sequesters or binds the benzoyl peroxide.
    • Evidence for a Narrower Interpretation: The term "microsponge" refers to a specific, known drug delivery technology. A defendant could argue that the claim is only intended to exclude that specific technology and its direct equivalents, and that other methods of stabilizing the active ingredient via polymeric interaction do not constitute "encapsulation" or "entrainment" as understood by a person of ordinary skill in the art.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Zydus's future commercial manufacture, use, and sale of its ANDA product will contribute to and induce infringement by others Compl. ¶49 Compl. ¶56 Compl. ¶61 Inducement would be based on the product label and instructions directing end-users to apply the infringing topical formulation for the treatment of acne Compl. ¶36
  • Willful Infringement: The complaint does not use the term "willful infringement," but it requests that the court declare the case "exceptional" under 35 U.S.C. § 285, which permits the award of attorney's fees Compl., Prayer for Relief ¶vii The factual basis for this appears to be Zydus's alleged pre-suit knowledge of the patents, based on their listing in the Orange Book and Zydus's act of sending a Paragraph IV certification letter challenging the patents Compl. ¶29 Compl. ¶37 Compl. ¶44

VII. Analyst's Conclusion: Key Questions for the Case

In this Hatch-Waxman litigation, where the accused product is designed to be a copy of the branded drug, the dispute will likely center on patent validity and claim construction rather than factual questions of infringement.

  • A core issue will be one of validity, specifically obviousness: given that combinations of these active ingredients were known in the art, a key question for the court will be whether it was obvious to a person of ordinary skill to combine all three in the claimed formulation with a reasonable expectation of success, or whether overcoming the known stability and efficacy challenges constituted a non-obvious inventive step.
  • A second central issue will be one of definitional scope: the case may turn on the construction of the term "gelling agent." The question will be whether this term is limited to the specific carbomer homopolymers used in the patent's preferred embodiments or broadly covers any agent, including a potentially different one used by Zydus, that can form a bioequivalent gel.
  • A third question will involve the scope of the negative limitation in the '467 Patent. The analysis will likely focus on whether Zydus's method of stabilizing the highly reactive benzoyl peroxide in its formulation creates a structure that, while not a formal "microsponge," could be considered a form of "encapsulation" or "entrainment," thereby avoiding infringement of that patent.
Loading Complaint